# Patient First Coalition Supports DEA’s Medical Cannabis Review Process > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-medical-cannabis-review-process-support/ > **Published:** 2026-06-01T10:37:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:53:48-04:00 > **Clinical Summary:** Explore how the DEA medical cannabis review process supported by the Patient First Coalition could reshape research and clinical access to cannabis therapies. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchMedical CannabisPharmaceuticalDEASchedule IIIPatient Advocacy Why This Matters Clinicians need to understand the regulatory pathway for cannabis rescheduling because it will directly impact their ability to prescribe, recommend, and access evidence-based dosing information for patients currently using cannabis therapeutically. The DEA’s medical cannabis review process and potential Schedule III transition could increase [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) opportunities, allowing providers to make evidence-based treatment decisions rather than relying on anecdotal reports or limited data. This regulatory shift enables pharmaceutical standardization and quality control, ensuring patients receive consistent, safe products with known cannabinoid profiles instead of variable street or unregulated market products. Clinical Summary The Patient First Coalition has endorsed the DEA’s medical cannabis review process, which aims to establish expert-driven pathways for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) as the drug potentially transitions from Schedule I to Schedule III status. This initiative represents a significant policy shift that could facilitate [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) by reducing regulatory barriers and enabling pharmaceutical-grade cannabis products to undergo standardized development and safety testing. The federal outreach effort seeks to accelerate evidence generation through collaboration between academic institutions, pharmaceutical companies, and regulatory bodies, addressing the current knowledge gap about cannabis efficacy and safety in specific clinical conditions. For clinicians, this regulatory evolution could eventually lead to FDA-approved cannabis-derived medications with established dosing, formulations, and clinical indications, moving cannabis therapeutics from anecdotal use toward evidence-based prescribing standards. Patients may gain access to standardized, quality-controlled products with predictable therapeutic effects and safety profiles once [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) progresses through the new review framework. Clinicians should monitor developments in the DEA’s rescheduling decision and emerging clinical evidence, as this could substantially change cannabis’s role in their therapeutic armamentarium within the next several years. Dr. Caplan’s Take “What we’re seeing with the DEA’s rescheduling process is finally an opportunity to conduct the rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) we’ve needed for two decades, and as physicians we have an obligation to participate in that research infrastructure rather than rely on anecdotal evidence from our clinical experience alone.” Clinical Perspective The Patient First Coalition’s support for the DEA’s medical cannabis rescheduling process reflects growing momentum toward expanding research access, which could eventually inform clinical evidence standards currently limited by Schedule I restrictions. However, clinicians should recognize that advocating for rescheduling and generating robust clinical data are distinct processes, and the transition to Schedule III status does not automatically validate efficacy or safety for any particular indication. The pharmaceutical industry’s increased involvement in this research pipeline introduces both opportunities for rigorous, well-designed trials and potential conflicts of interest that warrant careful scrutiny as results emerge. Until large-scale, high-quality randomized controlled trials establish clear risk-benefit profiles for specific cannabis formulations and conditions, clinical practice should remain cautious about incorporating cannabis recommendations beyond the limited evidence-supported indications currently recognized (such as cannabinoid use for chemotherapy-induced nausea). Practitioners caring for patients interested in medical cannabis should stay informed about ongoing DE 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Patient%20First%20Coalition%20Supports%20DEA%27s%20Medical%20Cannabis%20Review%20Process%20Providing%20Experts%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57042)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57042)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Patient%20First%20Coalition%20Supports%20DEA%27s%20Medical%20Cannabis%20Review%20Process%20Providing%20Experts%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57042)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://finance.yahoo.com/sectors/healthcare/articles/patient-first-coalition-supports-deas-124900935.html](https://finance.yahoo.com/sectors/healthcare/articles/patient-first-coalition-supports-deas-124900935.html) Further Reading CED Clinic Blog[What the 2026 DOJ Rescheduling Order Means in Practice](https://cedclinic.com/schedule-iii-medical-cannabis-federal-policy-change/) CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal Marijuana reclassification could reshape medical research and cannabis industry](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) Learn how federal marijuana rescheduling may impact [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and the cannabis industry landscape. [Read More](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) [How U.S. marijuana reclassification could help cannabis companies – The Detroit News](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) Explore the potential benefits of marijuana reclassification for cannabis companies and market growth. [Explore Insights](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) [The feds have embraced medical marijuana. Now what? – KOTA Territory News](https://cedclinic.com/topic-legalization-info/) Understand the implications of federal acceptance of medical marijuana and what it means for patients and providers. [Discover More](https://cedclinic.com/topic-legalization-info/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).